Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

Inclusion Criteria:

• The pathological diagnosis of recurrent or metastatic cervical cancer;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1;
• Life expectancy of more than 3months;

• With normal marrow, liver and renal function：

  • blood routine examination ：HB≥90g/L，ANC ≥1.5×10*9/L，PLT≥80×10*9/L；
  • Biochemical examination: total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL)，alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of ≤2.5 UNL or ≤5 UNL ，acreatinine (Cr) of ≤ 1.25 UNL; creatinine clearance rate ≥ 45ml/min (Cockcroft-Gault);
• With written informed consent signed voluntarily by patients themselves .
• With good compliance and agree to accept follow-up of disease progression and adverse events.

Exclusion Criteria:

• Uncontrolled hypertension
• Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias
• With abnormal coagulation function， bleeding tendency or treating with thrombolysis and anticoagulation
• History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood ≥ (++), and vasculitis) =< 3 months prior to randomization;
• uncured the wound or fracture
• Centrally located tumors of local invasion of major blood vessels, or Researchers think that patients may invade the important blood vessels and cause fatal bleeding (CT or MRI);
• Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction);
• Urine protein >++, or urine protein in 24 hours> 1.0g
• Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment
• History of uncontrolled psychotropic drug abuse or mental disorders;
• Prior VEGFR inhibitor treatment ;
• Other malignancy within Before or at the same time other than basal cell skin cancer, or carcinoma in situ of the cervix;